Plan to limit number of NHS patients diagnosed with ADHD attacked as ‘rationing’ healthcare

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-17T13:33:34.565Z • Permanent link

David Nutt, a British psychiatrist and professor of clinical psychopharmacology at Imperial College London, has long been a vocal advocate for a more nuanced approach to diagnosing attention deficit hyperactivity disorder (ADHD). In recent months, his concerns have come to the forefront of public debate in the United Kingdom. Proposals to limit the number of patients being formally diagnosed with ADHD have been met with fierce resistance from mental health professionals and patient advocacy groups, who argue that such measures would unfairly restrict access to treatment and stigmatize those who suffer from the condition.

The controversy surrounding ADHD diagnosis in the UK has its roots in the National Institute for Health and Care Excellence (NICE), a non-departmental public body that sets national priorities for healthcare in England. In 2022, NICE published guidelines for the diagnosis and treatment of ADHD, which some critics argue are overly restrictive and fail to account for the complexities of the condition. The review, expected to be published next week, is expected to say that patients should be "triaged" and offered support without formal diagnosis, sparking fears that the number of people being formally diagnosed with ADHD will be severely curtailed.

Nutt has long been a key figure in the debate over ADHD diagnosis, and his views have been influential in shaping the NICE guidelines. In a recent interview, he expressed his concerns about the proposed limits on diagnosis, arguing that they would "harm people who need help and undermine the trust between patients and clinicians." The debate has also attracted attention from other experts, including Dr. Russell A. Barkley, a renowned ADHD researcher and clinical psychologist at the University of North Carolina at Chapel Hill, who has warned that restrictive diagnosis limits could have "devastating consequences" for patients and families.

The proposed limits on ADHD diagnosis have significant implications for companies that manufacture medications and treatments for the condition. Companies such as Shire, a leading developer of ADHD medications, and Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, have seen their sales of ADHD medications skyrocket in recent years. A reduction in the number of people being formally diagnosed with ADHD could lead to a significant decline in sales, potentially impacting the financial performance of these companies.

The debate over ADHD diagnosis also has significant implications for research communities, which rely on large datasets of patients to develop new treatments and understand the underlying biology of the condition. A reduction in the number of people being formally diagnosed with ADHD could limit the availability of these datasets, making it more difficult for researchers to develop effective treatments and study the condition. In the United States, for example, the Centers for Disease Control and Prevention (CDC) estimates that over 9.4 million children and adults have been diagnosed with ADHD in the past year, providing a vast pool of data for researchers.

The debate over ADHD diagnosis is part of a broader pattern of restrictions on healthcare access in the UK, which has been driven by concerns over cost and resource allocation. In recent years, the UK government has introduced a range of measures aimed at reducing healthcare spending, including the National Health Service (NHS) long-term plan, which sets out a vision for transforming the NHS and reducing waiting times. However, critics argue that these measures have led to a " postcode lottery" of healthcare access, where patients in different parts of the country receive different levels of care.